PL3630098T3 - Połączenie antagonisty receptora 5-ht6 i inhibitora acetylocholinoesterazy do zastosowania w leczeniu choroby alzheimera w subpopulacji pacjentów posiadających allele apoe4 - Google Patents

Połączenie antagonisty receptora 5-ht6 i inhibitora acetylocholinoesterazy do zastosowania w leczeniu choroby alzheimera w subpopulacji pacjentów posiadających allele apoe4

Info

Publication number
PL3630098T3
PL3630098T3 PL18726791T PL18726791T PL3630098T3 PL 3630098 T3 PL3630098 T3 PL 3630098T3 PL 18726791 T PL18726791 T PL 18726791T PL 18726791 T PL18726791 T PL 18726791T PL 3630098 T3 PL3630098 T3 PL 3630098T3
Authority
PL
Poland
Prior art keywords
alzheimer
disease
treatment
combination
receptor antagonist
Prior art date
Application number
PL18726791T
Other languages
English (en)
Inventor
Kristian WINDFELD
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of PL3630098T3 publication Critical patent/PL3630098T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18726791T 2017-05-24 2018-05-22 Połączenie antagonisty receptora 5-ht6 i inhibitora acetylocholinoesterazy do zastosowania w leczeniu choroby alzheimera w subpopulacji pacjentów posiadających allele apoe4 PL3630098T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201700313 2017-05-24
DKPA201700538 2017-09-29
EP18726791.9A EP3630098B1 (en) 2017-05-24 2018-05-22 Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
PCT/EP2018/063402 WO2018215478A1 (en) 2017-05-24 2018-05-22 Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles

Publications (1)

Publication Number Publication Date
PL3630098T3 true PL3630098T3 (pl) 2021-09-06

Family

ID=62235961

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18726791T PL3630098T3 (pl) 2017-05-24 2018-05-22 Połączenie antagonisty receptora 5-ht6 i inhibitora acetylocholinoesterazy do zastosowania w leczeniu choroby alzheimera w subpopulacji pacjentów posiadających allele apoe4

Country Status (22)

Country Link
US (1) US11464759B2 (pl)
EP (1) EP3630098B1 (pl)
JP (1) JP7167065B2 (pl)
KR (1) KR102676011B1 (pl)
CN (1) CN111032038A (pl)
AU (1) AU2018272883B2 (pl)
BR (1) BR112019001145A2 (pl)
CA (1) CA3063968A1 (pl)
CY (1) CY1124282T1 (pl)
DK (1) DK3630098T3 (pl)
ES (1) ES2869128T3 (pl)
HR (1) HRP20210634T1 (pl)
HU (1) HUE053636T2 (pl)
LT (1) LT3630098T (pl)
MX (1) MX2019013912A (pl)
PL (1) PL3630098T3 (pl)
PT (1) PT3630098T (pl)
RS (1) RS61704B1 (pl)
SG (1) SG11201909895UA (pl)
SI (1) SI3630098T1 (pl)
WO (1) WO2018215478A1 (pl)
ZA (1) ZA201907525B (pl)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372768T1 (de) 2001-03-29 2007-09-15 Lilly Co Eli N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
PT1529116E (pt) * 2002-08-07 2009-09-10 Novartis Ag Métodos para o tratamento da demência com base no genótipo da apo e
WO2008143361A1 (en) 2007-05-22 2008-11-27 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
RU2369600C1 (ru) * 2008-01-24 2009-10-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US8404711B2 (en) 2009-04-13 2013-03-26 Theravance, Inc. 5-HT4 receptor agonist compounds for treatment of cognitive disorders
WO2014165701A1 (en) 2013-04-03 2014-10-09 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JP2018519358A (ja) 2015-05-07 2018-07-19 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh 神経変性疾患を処置する方法
RU2742173C2 (ru) * 2016-04-26 2021-02-02 Х. Лундбекк А/C Применение ингибитора ацетилхолинэстеразы и идалопирдина для снижения риска падений у пациентов с болезнью паркинсона
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity

Also Published As

Publication number Publication date
CY1124282T1 (el) 2022-07-22
EP3630098B1 (en) 2021-03-24
SG11201909895UA (en) 2019-11-28
SI3630098T1 (sl) 2021-07-30
LT3630098T (lt) 2021-05-25
EP3630098A1 (en) 2020-04-08
HUE053636T2 (hu) 2021-07-28
RU2019135609A (ru) 2021-06-24
HRP20210634T1 (hr) 2021-05-28
JP7167065B2 (ja) 2022-11-08
AU2018272883B2 (en) 2024-02-15
DK3630098T3 (da) 2021-04-26
KR102676011B1 (ko) 2024-06-17
US11464759B2 (en) 2022-10-11
MX2019013912A (es) 2020-01-21
US20180353477A1 (en) 2018-12-13
RS61704B1 (sr) 2021-05-31
AU2018272883A1 (en) 2019-11-14
WO2018215478A1 (en) 2018-11-29
CN111032038A (zh) 2020-04-17
PT3630098T (pt) 2021-04-21
BR112019001145A2 (pt) 2019-04-30
ES2869128T3 (es) 2021-10-25
KR20200007795A (ko) 2020-01-22
RU2019135609A3 (pl) 2021-08-23
CA3063968A1 (en) 2018-11-29
JP2020520964A (ja) 2020-07-16
ZA201907525B (en) 2022-02-23

Similar Documents

Publication Publication Date Title
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
EP3829628C0 (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF C5-RELATED DISEASE
GB201917974D0 (en) Apparatus and system for measuring one or more parameters of a person's foot
SG11202004408YA (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
IL264040A (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
IL284175A (en) Dosing regimens in the use of LY3154207 in the treatment of diseases of the dopaminergic central nervous system
IL262546B (en) Use of an acetylcholinesterase inhibitor and idalopyridine to reduce falls in Parkinson's patients
PT3937948T (pt) Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares
ZA201907525B (en) Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
MX2018014184A (es) Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
PT3648761T (pt) Telmisartan para a profilaxia ou tratamento de hipertensão em gatos
PT3600276T (pt) Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo
SG10201801200PA (en) An h3 receptor antagonist for use in the treatment of alzheimer's disease
PL3413870T3 (pl) Igmezyna do zastosowania do leczenia choroby alzheimera
IL267716A (en) Drug combination therapies that use drugs designed for bone and bone-related diseases
IL271795A (en) A screening platform to identify drugs or medical substances for the treatment of Alzheimer's disease
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases